Sedana Medical AB (SE:SEDANA)
:SEDANA
Want to see SE:SEDANA full AI Analyst Report?
Top Page
Sedana Medical AB
(SEDANA)
Select Model
Select Model
Rating:49Neutral
Price Target:
kr9.50
▼(-11.38% Downside)
Action:ReiteratedDate:04/24/26
The score is held back primarily by weak financial performance—ongoing losses, flat-to-down revenue, and negative operating/free cash flow—despite a very low-debt balance sheet. Technical indicators are moderately supportive in the near term, but valuation is constrained by negative earnings and no dividend data.
Positive Factors
Very low leverage
An extremely low debt load gives Sedana durable financial flexibility while it scales commercial and regulatory activities. With limited interest burden, management can fund R&D and market rollout from equity/liquidity, reducing near-term default risk during cash burn.
Negative Factors
Structural operating losses
Persistent negative EBIT and large net losses erode shareholder value and signal that current revenue and cost structure do not yet generate operating profit. Without sustained margin improvement or revenue expansion, losses will continue to pressure equity and strategic options.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
An extremely low debt load gives Sedana durable financial flexibility while it scales commercial and regulatory activities. With limited interest burden, management can fund R&D and market rollout from equity/liquidity, reducing near-term default risk during cash burn.
Read all positive factors
Sedana Medical AB (SEDANA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr1.02B
Dividend YieldN/A
Average Volume (3M)247.68K
Price to Earnings (P/E)―
Beta (1Y)0.77
Revenue Growth4.66%
EPS Growth27.83%
CountrySE
Employees113
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.04
Shares Outstanding99,336,960
10 Day Avg. Volume186,290
30 Day Avg. Volume247,675
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.13
Price to Sales (P/S)5.10
P/FCF Ratio-13.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.26
Revenue Forecast (FY)kr213.23M
Sedana Medical AB Business Overview & Revenue Model
Company Description
Sedana Medical AB (publ), a medical technology company, develops, markets, and sells medical devices in Sweden and internationally. The company offers Sedaconda ACD-L and Sedaconda ACD-, which are disposable medical devices that enables the admini...
How the Company Makes Money
Sedana Medical generates revenue primarily by selling consumable ICU sedation products tied to the use of inhaled anesthetics in ventilated patients. A core revenue stream is the sale of its Sedaconda ACD devices (disposable/consumable components ...
Sedana Medical AB Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
74
Positive
Cash Flow
26
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 196.15M | 200.23M | 178.75M | 153.87M | 122.86M | 159.15M |
| Gross Profit | 139.83M | 142.71M | 126.14M | 108.98M | 86.07M | 106.71M |
| EBITDA | -7.36M | -10.12M | -4.03M | -51.67M | -64.87M | -49.10M |
| Net Income | -39.52M | -59.24M | -10.67M | -59.61M | -73.51M | -57.97M |
Balance Sheet | ||||||
| Total Assets | 960.23M | 954.46M | 1.02B | 1.01B | 1.08B | 1.17B |
| Cash, Cash Equivalents and Short-Term Investments | 80.68M | 90.98M | 193.96M | 381.80M | 607.74M | 836.18M |
| Total Debt | 7.56M | 4.70M | 5.92M | 4.31M | 8.74M | 8.87M |
| Total Liabilities | 62.33M | 53.68M | 61.17M | 44.06M | 52.43M | 66.12M |
| Stockholders Equity | 897.90M | 900.78M | 958.23M | 970.00M | 1.03B | 1.10B |
Cash Flow | ||||||
| Free Cash Flow | -47.84M | -75.19M | -186.77M | -206.95M | -253.22M | -151.48M |
| Operating Cash Flow | -16.10M | -12.78M | -11.77M | -38.06M | -115.43M | -41.22M |
| Investing Cash Flow | -59.37M | -63.03M | -44.67M | -321.96M | -137.78M | -110.25M |
| Financing Cash Flow | -4.13M | -4.04M | -3.57M | -4.86M | -1.51M | 605.07M |
Sedana Medical AB Technical Analysis
Positive
10.72
Price Trends
9.22
Positive
9.69
Positive
11.43
Negative
Market Momentum
0.12
Negative
61.85
Neutral
81.77
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SEDANA, the sentiment is Positive. The current price of 10.72 is above the 20-day moving average (MA) of 9.02, above the 50-day MA of 9.22, and below the 200-day MA of 11.43, indicating a neutral trend. The MACD of 0.12 indicates Negative momentum. The RSI at 61.85 is Neutral, neither overbought nor oversold. The STOCH value of 81.77 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SEDANA.
Sedana Medical AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | kr1.15B | -74.03 | -4.20% | ― | 23.85% | -135.36% | |
55 Neutral | kr847.55M | 103.06 | 6.93% | ― | -5.76% | -81.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr1.02B | -61.68 | -4.42% | ― | 4.66% | 27.83% | |
48 Neutral | kr731.05M | -7.33 | -36.55% | ― | 48.53% | 17.86% | |
48 Neutral | kr212.54M | -5.27 | -18.55% | ― | 3.85% | -70.92% | |
47 Neutral | kr459.10M | -24.57 | ― | ― | 34.51% | 6.00% |
* Healthcare Sector Average
SE:SEDANA
Sedana Medical AB
10.22
0.00
0.00%
SE:PAX
Paxman AB
49.40
-27.00
-35.34%
SE:SEZI
Senzime AB
4.65
-0.18
-3.73%
SE:CRAD.B
C-Rad AB Class B
25.10
-4.90
-16.33%
SE:INTEG.B
Integrum AB Class B
7.97
-5.52
-40.91%
SE:OSSD
OssDsign AB
4.15
-9.15
-68.80%
Sedana Medical AB Corporate Events
Sedana Medical Calls AGM to Vote on Governance and New Incentive Plan
Apr 24, 2026
Sedana Medical AB has called its annual general meeting for 27 May 2026 in Danderyd, Sweden, setting the timetable and procedural rules for shareholders to participate, including registration deadlines and requirements for nominee-registered share...
Sedana Medical Turns Positive EBITDA Despite Softer Q1 Sales
Apr 23, 2026
Sedana Medical reported first‑quarter 2026 net sales of SEK 53.4 million, down 7% year on year, though the gross margin held steady at 71% and the company achieved a positive Group EBITDA of SEK 1.8 million. EBITDA excluding the U.S. improve...
Sedana Medical Posts Record Sales and Advances Toward U.S. ICU Sedation Market
Apr 14, 2026
Sedana Medical reports record sales and a profitable core business outside the U.S., underscoring strong traction for its inhaled sedation products in established markets. The company highlights a structured commercial footprint through direct sal...
Sedana Medical sets April 23 date for first‑quarter 2026 results and investor presentation
Apr 10, 2026
Sedana Medical, a specialist in inhaled sedation solutions for intensive care, will report results for the first quarter of 2026 on April 23. The Swedish medtech and pharmaceutical company markets its Sedaconda ACD device and Sedaconda (isoflurane...
Sedana Medical Treats First U.S. Patient in FDA-Approved Early Access Sedation Program
Mar 13, 2026
Sedana Medical has treated the first U.S. patient under its FDA‑approved Early Access Program, giving critically ill “difficult‑to‑sedate” intensive care patients access to its investigational inhaled isoflurane‑...
Sedana Medical Narrows Losses and Turns Ex-US EBITDA Positive Amid 2025 Sales Growth
Feb 12, 2026
Sedana Medical reported 5% year-on-year net sales growth in the fourth quarter of 2025 to SEK 51.8 million, or 11% at constant exchange rates, with gross margin improving to 73%. EBITDA turned slightly positive at group level and reached an 8% mar...
Sedana Medical Schedules Q4 2025 Interim Report Release and Investor Presentation
Jan 29, 2026
Sedana Medical AB will publish its interim report for the fourth quarter of 2025 on 12 February 2026 at around 07:00 CET and will present the results later the same day at 13:30 CET via an audiocast and teleconference. The presentation, led by CEO...
Sedana Medical Strengthens Leadership with New CFO Ahead of US Expansion
Jan 27, 2026
Sedana Medical has appointed experienced finance executive Mikael Haag as its new Chief Financial Officer and member of the Executive Management Team, with him set to assume the role no later than July 2026, while current CFO Johan Spetz will stay...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.